Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: A morphologic and functional study

Retina

Volumn 33, Issue 2, 2013, Pages 397-402

  Rinaldi, Michele ^a   Chiosi, Flavia ^a   Dell'Omo, Roberto ^b   Romano, Mario R ^b   Parmeggiani, Francesco ^c   Semeraro, Francesco ^d   Menzione, Massimo ^a   Costagliola, Ciro ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

best visual acuity; foveal central thickness; microperimetry; myopic choroidal neovascularization; pegaptanib

Indexed keywords

PEGAPTANIB; VASCULOTROPIN 165;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MALE; MYOPIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIMETRY; PILOT STUDY; PROSPECTIVE STUDY; RETINA FOVEA; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT DURATION; VISUAL ACUITY;

EID: 84873412511     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318261a73c     Document Type: Article

References (31)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-213.
2. Tokoro T. Criteria for diagnosis of pathologic myopia. In: Tokoro T, ed. Atlas of Posterior Fundus Changes in Pathologic Myopia. New York, NY: Springer Verlag; 1998:1-2.
3. Sperduto RD, Seigel D, Roberts J, et al. Prevalence of myopia in the United States. Arch Ophthalmol 1983;101:405-407.
4. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 2003;110:1297-1305.
5. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 2003;87:570-573.
6. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-2067.
7. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-673.
8. Gragoudas ES, Adamis AP, Cunningham ET, et al; VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
9. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year two efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113: 1508-1521.
10. Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010;248:543-550.
11. Cohen SY. Anti-VEGF drugs as the 2009 first line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-1066.
12. Ouhadj O, Bouarfa A, Akel S, et al. Intravitreal ranibizumab injections for the treatment of choroidal neovascularization complicating high myopia. J Fr Ophtalmol 2010;33:649-654.
13. Calvo-Gonzalez C, Reche-Frutos J, Donate J, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: Factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 2011;151:529-534.
14. Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010;3:418-424.
15. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: Intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. Am J Ophthalmol 2010;149:458-464.
16. Bennet MD, Yee W. Pegapatanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007;245:903-905.
17. Rosina C, Bottoni F, Staurenghi G. Clinical experience with pegapatnib sodium. Clin Ophthalmol 2008;2:485-488.
18. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141: 456-462.
19. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008;28: 1308-1313.
20. Vadalà M, Pece A, Cipolla S, et al. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopiä A long-term follow-up study. Br J Opthalmol 2011;95:657-661.
21. Lai TY, Chan WM, Liu DT, et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-756.
22. Kostantidinis L, Mantel I, Pournaras JAC, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:311-318.
23. Mones JM, Amselm L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009;23:1275-1280.
24. Neri P, Mariotti C, Arapi I, et al. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: Is this the new deal? Curr Med Res Opin 2012;28:395-400.
25. Sultan MB, Zhou D, Loftus J, et al. Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;118:1107-1118.
26. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
27. Wroblewski JJ, Wells JA III, Adamis AP, et al. Pegaptanib in Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127:374-380.
28. Scupola A, Tiberti AC, Sasso P, et al. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: One-year results. Retina 2010;30:739-747.
29. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;118:327-336.
30. Verteporfin in Photodynamic Theory Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108: 841-852.
31. Montero JA, Ruiz-Moreno JM. Treatment of choroidal neovascularization in high myopia. Curr Drug Targets 2010;11: 630-644.